High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults
New England Journal of Medicine · 11.12.2025 · 393 (23) · 2291-2302
DOI: 10.1056/nejmoa2509907 ↗Kurz gefasst
Klinische Studie (Phase IV) in der Zeitschrift New England Journal of Medicine, erschienen am 11.12.2025. Verfasst von Niklas Dyrby Johansen und 37 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen. Hauptthemen laut MEDLINE: Hospitalization, Influenza Vaccines, Influenza, Human, Pneumonia. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Sanofi, Sanofi Pasteur.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
BACKGROUND: High-dose inactivated influenza vaccine has been shown to provide protection against influenza that is superior to that with the standard dose. However, data from individually randomized trials on the effectiveness of the high-dose vaccine against severe outcomes are limited. METHODS: In this pragmatic, open-label, randomized, controlled trial conducted in Denmark during the 2022-2023, 2023-2024, and 2024-2025 influenza seasons, we assigned older adults (≥65 years of age) to receive the high dose of the inactivated influenza vaccine or the standard dose. Data collection relied on nationwide administrative health registries. The primary end point was hospitalization for influenza or pneumonia that occurred from 14 days after vaccination through May 31 of the following year. RESULTS: Of the 332,438 participants who underwent randomization, 166,218 were assigned to receive the high-dose vaccine and 166,220 to receive the standard-dose vaccine. The mean (±SD) age of the participants was 73.7±5.8 years, and 161,538 participants (48.6%) were women. A primary end-point event occurred in 1138 participants (0.68%) in the high-dose group and in 1210 (0.73%) in the standard-dose group (relative vaccine effectiveness, 5.9%; 95.2% confidence interval [CI], -2.1 to 13.4; P = 0.14). Hospitalization for influenza occurred in 0.06% of the participants in the high-dose group and in 0.11% of those in the standard-dose group (relative vaccine effectiveness, 43.6%; 95.2% CI, 27.5 to 56.3); hospitalization for pneumonia occurred in 0.63% and 0.63%, respectively (relative effectiveness, 0.5%; 95.2% CI, -8.6 to 8.8); hospitalization for cardiorespiratory disease in 2.25% and 2.38% (relative effectiveness, 5.7%; 95.2% CI, 1.4 to 9.9); hospitalization for any cause in 9.38% and 9.58% (relative effectiveness, 2.1%; 95.2% CI, -0.1 to 4.3), and death from any cause in 0.67% and 0.66% (relative effectiveness, -2.5%; 95.2% CI, -11.6 to 5.9). The incidence of serious adverse events was similar in the two groups. CONCLUSIONS: In this trial, a high-dose inactivated influenza vaccine did not result in a significantly lower incidence of hospitalization for influenza or pneumonia than a standard dose among older adults. (Funded by Sanofi; DANFLU-2 ClinicalTrials.gov number, NCT05517174; EU Clinical Trials Register number, 2022-500657-17-00.).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen.
- Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen.
- Sanofi, Morristown, NJ.
- Department of Epidemiology, University of Delaware, Newark.
- Sanofi, Singapore.
- Sanofi, Lyon, France.
ORCID-Profile: Niklas Dyrby Johansen, Daniel Modin, Scott D Solomon, Martin J Landray
Förderung
- Sanofi
- Sanofi Pasteur
Zitieren
APA
Johansen, N. D., Modin, D., Loiacono, M. M., Harris, R. C., Dufournet, M., Larsen, C. S., Larsen, L., Wiese, L., Dalager-Pedersen, M., Claggett, B. L., Janstrup, K. H., Bartholdy, K. V., Bernholm, K. F., Borchsenius, J. I. H., Davidovski, F. S., Davodian, L. W., Dons, M., Duus, L. S., Espersen, C., …, & Biering-Sørensen, T. (2025). High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults. New England Journal of Medicine, 393(23), 2291-2302. https://doi.org/10.1056/nejmoa2509907
Vancouver
Johansen ND, Modin D, Loiacono MM, Harris RC, Dufournet M, Larsen CS, et al. High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults. New England Journal of Medicine. 2025;393(23):2291-2302. doi:10.1056/nejmoa2509907
BibTeX
@article{Johansen2025,
author = {Johansen, Niklas Dyrby and Modin, Daniel and Loiacono, Matthew M and Harris, Rebecca C and Dufournet, Marine and Larsen, Carsten Schade and Larsen, Lykke and Wiese, Lothar and Dalager-Pedersen, Michael and Claggett, Brian L and Janstrup, Kira Hyldekær and Bartholdy, Katja Vu and Bernholm, Katrine Feldballe and Borchsenius, Julie Inge-Marie Helene and Davidovski, Filip Soeskov and Davodian, Lise Witten and Dons, Maria and Duus, Lisa Steen and Espersen, Caroline and Fussing, Frederik Holme and Jensen, Anne Marie Reimer and Landler, Nino Emanuel and Langhoff, Adam Cadovius Femerling and Lassen, Mats Christian Højbjerg and Nielsen, Anne Bjerg and Ottosen, Camilla Ikast and Sengeløv, Morten and Skaarup, Kristoffer Grundtvig and Solomon, Scott D and Landray, Martin J and Gislason, Gunnar H and Køber, Lars and Ralfkiaer, Line and Nealon, Joshua and Sivapalan, Pradeesh and Martel, Cyril Jean-Marie and Jensen, Jens Ulrik Stæhr and Biering-Sørensen, Tor},
title = {High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults},
journal = {New England Journal of Medicine},
year = {2025},
volume = {393},
number = {23},
pages = {2291--2302},
doi = {10.1056/nejmoa2509907}
}
EUVIMED